Product information
From Health Canada
The product monograph is developed by a drug sponsor according to guidelines published by Health Canada that provide direction on the content and format. The veterinary labelling is developed by the drug sponsor according to the Food and Drug Regulations. While Health Canada reviews the product monograph or the veterinary labelling as part of the drug review process, it remains the responsibility of the drug sponsor to ensure that the product monograph or the veterinary labelling is complete and accurate.
Current status:
Cancelled Post Market
Current status date:
2016-08-04
Original market date: See footnote 1
1997-04-30
Product name:
CEREZYME
DIN:
02230694
Product Monograph/Veterinary Labelling:
Date:
2014-04-15
Product monograph/Veterinary Labelling (PDF version ~ 175K)
Company:
SANOFI GENZYME, A DIVISION OF SANOFI-AVENTIS CANADA INC
1755 Steeles Avenue West
Toronto
Ontario
Canada
M2R 3T4
Class:
Human
Dosage form(s):
Powder For Solution
Route(s) of administration:
Intravenous
Number of active ingredient(s):
1
Schedule(s):
Schedule D , Prescription
American Hospital Formulary Service (AHFS): See footnote 3
44:00.00
Anatomical Therapeutic Chemical (ATC): See footnote 4
A16AB02 IMIGLUCERASE
Active ingredient group (AIG) number:See footnote5
0131511001
| Active ingredient(s) | Strength |
|---|---|
| IMIGLUCERASE | 200 UNIT / VIAL |